iCAD’s Innovative Leadership in Mammography AI Shined at RSNA 2023: A Recap of Key Events
Attendees at this year’s Radiological Society of North America (RSNA) 2023 Annual Meeting witnessed iCAD’s prominent presence, showcasing groundbreaking advancements in the field of breast imaging and artificial intelligence (AI). iCAD, a global medical technology leader in innovative cancer detection solutions, made headlines with new clinical data, shared exciting partnership...
Revolutionary Advancements in Mammography AI: Lifesaving Breakthroughs
Every October, we shine a spotlight on breast cancer during National Breast Cancer Awareness Month. Thanks to the remarkable innovations in AI (Artificial Intelligence), we have more reasons to raise awareness about advancements in mammography than ever before. AI-powered mammography is revolutionizing care for patients’ breast health by finding cancers...
Embracing Clarity: Celebrating the 2nd Annual World Dense Breast Day
At iCAD, we are recognizing the 2nd annual World Dense Breast Day today, a day that holds significant importance, not only for the women who may have dense breasts but for all of us dedicated to advancing breast health awareness and early cancer detection. As we gather to mark this...
Joining Forces with Google to Revolutionize Breast Cancer Screening Worldwide
by Dana Brown, President and CEO of iCAD, Inc. We’ve joined forces with Google Health once again to address two of the most pressing challenges in healthcare: the global radiologist shortage and significant disparities in healthcare. Per our 20-year worldwide agreement, Google’s AI technology will seamlessly integrate into our ProFound...
What is Breast Density?
A woman’s breast is primarily made up of fat and fibroglandular breast tissue, which is the network of milk glands and ducts designed to produce and transport milk to the nipple for breast feeding. Fibrous tissue, also known as connective tissue, supports the breast and holds everything in place. When...
What is CAD?
Computer-Aided Detection (CAD) is a sophisticated FDA-approved technology that helps radiologists identify characteristics that may be associated with various forms of cancer. By using iCAD patented algorithms to mark suspicious areas, CAD serves as a “second pair of eyes” and acts very much like a “spell checker” to identify characteristics...
Why RCI Became the First in the State to Adopt ProFound AI as its Breast AI Solution for Mammography
Iowa’s largest radiology group, Radiology Consultants of Iowa (RCI), offers a wide range of imaging services for patients, including breast cancer screening. In addition to the mammograms done at their imaging center, which is accredited by the American College of Radiology (ACR) as a Breast Imaging Center of Excellence, RCI...
New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen hadalmost 20 times higher risk of developing breast cancer in the next year than the general risk population iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT)...
Why ProFound AI Prevailed as the Premier AI Solution in a Competitive Trial at Wake Radiology
With 14 imaging locations in the Raleigh-Durham metropolitan area, also known as “the Triangle,” Wake Radiology offers a wide array of imaging exams in the outpatient setting, including both screening and diagnostic mammography. Renowned for state-of-the-art care, in August 2013 Wake Radiology began to upgrade to 3D mammography, or DBT,...